Datapoint: Libtayo Scores NSCLC Nod, Will Take On Keytruda

Sanofi and Regeneron’s Libtayo last week scored its third FDA approval, this time for first-line treatment of advanced non-small cell lung cancer (NSCLC) in patients whose tumors have high PD-L1 expression. The drug will now have to face off against Merck’s Keytruda, a behemoth in the competitive lung cancer market basket. For the treatment of NSCLC, Keytruda currently holds preferred formulary placement for 6% of all covered lives, growing to 17% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 2/24/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 17

Datapoint: Oscar to Exit Two States

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 16

Datapoint: AstraZeneca, Daiichi Score Earlier Breast Cancer Use for Enhertu

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 12

Datapoint: Pfizer Inks Biohaven Deal

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today